Ti/Zr/O Mixed Oxides for the Catalytic Transfer Hydrogenation of Furfural to GVL in a Liquid-Phase Continuous-Flow Reactor

This work aims to develop an efficient catalyst for the cascade reaction from furfural to y-valerolactone in a liquid-phase continuous reactor. This process requires both Lewis and Brønsted acidity; hence, a bifunctional catalyst is necessary to complete the one-pot reaction. Ti/Zr/O mixed oxide-based catalysts were chosen to this end as balancing metal oxide composition allows the acidity characteristics of the overall material to be modulated. Oxides with different compositions were then synthesized using the co-precipitation method. After characterization via porosimetry and NH3-TPD, the catalyst with equimolar quantities of the two components was demonstrated to be the best one in terms of superficial area (279 m2/g) and acid site density (0.67 mmol/g). The synthesized materials were then tested using a plug flow reactor at 180 C, with a 10 min contact time. Ti/Zr/O (1:1) was demonstrated to be the most promising catalyst during the recycling tests as it allowed obtaining the highest selectivities in the desired products (about 45% in furfuryl isopropyl ether and 20% in y-valerolactone) contemporaneously with 100% furfural conversion

Changing the paradigm in postherpetic neuralgia treatment: lidocaine 700 mg medicated plaster

OBJECTIVE: Chronic pain is currently considered a disease state with biopsychosocial consequences and a negative impact on patients' quality of life (QoL). Pain from postherpetic neuralgia (PHN) can persist for months or years and is a prototypical example of chronic pain. We analyzed PHN as a model of chronic pain. including its effects on QoL and clinical aspects. We explored treatment options, focusing on the topical treatment with lidocaine 700 mg medicated plaster (LMP) and how this impacts PHN management.MATERIALS AND METHODS: This article is a narrative review of published studies. Preclinical and clinical studies were retrieved from literature through a search performed in PubMed/MEDLINE.RESULTS: To choose the appropriate treatment for chronic pains, such as PHN, not only efficacy but also tolerability, manageability, practicality, and compliance are important factors. especially in the long term. It is also important to set treatment expectations with the patients as total suppression of pain may be unrealistic. and a balance needs to be found between pain control and the minimization of adverse events. In this respect, LMP may be the best currently available treatment: it is easy to use, has low systemic absorption and thus a low risk for pharmacological interactions. Therefore, treatments can be personalized, and concomitant medications can be added, if needed. Recent data from a real-world study support this view by showing that LMP has superior effectiveness in reducing pain and improving the QoL compared to other commonly used systemic treatments and confirming its good tolerability profile that is mainly characterized by localized skin reactions.CONCLUSIONS: LMP is one of the best currently available treatment options for PHN patients balancing good efficacy with an excellent tolerability profile and can therefore be considered for use as a first-line treatment for PHN

Salification Controls the In-Vitro Release of Theophylline

Sustained released formulation is the most used strategy to control the efficacy and the adverse reactions of an API (active pharmaceutical ingredient) with a narrow therapeutic index. In this work, we used a different way to tailor the solubility and diffusion of a drug. Salification of Theophylline with Squaric Acid was carried out to better control the absorption of Theophylline after administration. Salification proved to be a winning strategy decreasing the dissolution of the APIs up to 54% with respect to Theophylline. Most importantly, this was accomplished in the first 10 min of the dissolution process, which are the most important for the API administration. Two polymorphs were identified and fully characterized. Theophylline squarate was discovered as trihydrate (SC-XRD) and as a metastable anhydrous form. Indeed, during the Variable Temperature-XRPD experiment, the trihydrate form turned back into the two starting components after losing the three molecules of water. On the other hand, the synthesis of the trihydrate form was observed when a simple mixing of the two starting components were exposed to a high humidity relative percentage (90% RH)

Vapor phase Beckmann rearrangement using high silica zeolite catalyst

Vapor phase Beckmann rearrangement of cyclohexanone oxime to e-caprolactam has been studied using high silica zeolite catalysts. Catalysts with different crystal sizes and gel-ageing times have been activated by ionic exchange in different conditions by means of a highly basic solution and a nearly neutral solution both containing ammonium salts. Samples have been calcined at different temperatures in order modify the number of defective sites. We observed that samples exchanged by means of a highly basic solution (pH > 10)1,2 and calcined at a relatively lower temperature (450 C) show the most interesting catalytic results. X-ray powder diffraction patterns of these samples show2 retention of the unit cell symmetry (orthorhombic cell) if compared to the dried sample. NH3-TPD confirms the low acidity of high silica zeolites, however a higher amount of desorbed ammonia is observed for the samples exchanged at higher pH and calcined at 450 C. Due to silanol nests the IR spectra of the same samples show the formation of Si\u2013NH2 bonds which are absent in the same material exchanged by other methods. Such sites seem to promote the high stability of the high silica zeolite catalysts also to the regeneration which is needed to remove the heavy carbonaceous compounds from the catalyst surface

Good manufacturing practices in autologous chondrocyte implantation: the experience in a public hospital

n/

MCM-41 supported co-based bimetallic catalysts for aqueous phase transformation of glucose to biochemicals

The transformation of glucose into valuable biochemicals was carried out on different MCM-41-supported metallic and bimetallic (Co, Co-Fe, Co-Mn, Co-Mo) catalysts and under different reaction conditions (150 °C, 3 h; 200 °C, 0.5 h; 250 °C, 0.5 h). All catalysts were characterized using N2 physisorption, Temperature Programmed Reduction (TPR), Raman, X-ray Diffraction (XRD) and Temperature Programmed Desorption (TPD) techniques. According to the N2-physisorption results, a high surface area and mesoporous structure of the support were appropriate for metal dispersion, reactant diffusion and the formation of bioproducts. Reaction conditions, bimetals synergetic effects and the amount and strength of catalyst acid sites were the key factors affecting the catalytic activity and biochemical selectivity. Sever reaction conditions including high temperature and high catalyst acidity led to the formation mainly of solid humins. The NH3-TPD results demonstrated the alteration of acidity in different bimetallic catalysts. The 10Fe10CoSiO2 catalyst (MCM-41 supported 10 wt. þ, 10 wt. %Co) possessing weak acid sites displayed the best catalytic activity with the highest carbon balance and desired product selectivity in mild reaction condition. Valuable biochemicals such as fructose, levulinic acid, ethanol and hydroxyacetone were formed over this catalyst

Aquivion® PFSA-based spray-freeze dried composite materials with SiO2 and TiO2 as hybrid catalysts for the gas phase dehydration of ethanol to ethylene in mild conditions

Aquivion PFSA resin, a perfluorinated ion-exchange polymer, has been used as a heterogeneous strong acid catalyst for a range of reactions; however, the activity of this material is limited due to the extremely low surface area of the polymer. In this paper we described the one-step synthesis of Aquivion® PFSA-based hybrid materials using heterocoagulation and spray-freeze-drying of sols containing the precursor of the active phases. The intimated encapsulation of different nano-oxides, such as TiO2 and SiO2 in the superacid resin matrix was easily obtained using this technique and compared with similar catalysts prepared by the impregnation conventional route. The approach led to the preparation of porous micro-granules characterised by a high homogeneity in the phase distribution and high surface area. The prepared materials were active and selective for the gas phase dehydration of ethanol to ethylene in mild conditions. The increase of the porosity improved the activity of the composites, compared to the pure Aquivion® PFSA, and allowed to reduce the amount of the superacid resin. Moreover, the type of encapsulated oxide, TiO2 or SiO2, modified the improved performance of the catalysts, having TiO2 the higher efficiency for ethanol conversion and selectivity in ethylene at very low temperature

Capsaicin 8% dermal patch in clinical practice: an expert opinion

Introduction: Neuropathic pain (NP) is caused by a lesion or disease of the somatosensory system, which can severely impact patients’ quality of life. The current-approved treatments for NP comprise of both centrally acting agents and topical drugs, including capsaicin 8% dermal patches, which is approved for the treatment of peripheral NP. / Areas covered: The authors summarize literature data regarding capsaicin use in patients who suffer from NP and discuss the clinical applications of this topical approach. / Expert opinion: Overall, the capsaicin 8% dermal patch is as effective in reducing pain intensity as other centrally active agents (i.e. pregabalin). Some studies have also reported fewer systemic side effects, a faster onset of action and superior treatment satisfaction compared with systemic agents. In our opinion, capsaicin 8% dermal patches also present additional advantages, such as a good systemic tolerability, the scarcity of adverse events, the possibility to combine it with other agents, and a good cost-effective profile. It is important to note that, as the mechanism of action of capsaicin 8% is the ‘defunctionalization’ of small afferent fibers through interaction with TRPV1 receptors, the peripheral expression of this receptor on nociceptor fibers, is crucial to predict patient’s response to treatment